genedrive
plc
("genedrive" or the
"Company")
Application for
Listing
Total Voting
Rights
genedrive plc (AIM: GDR), the point
of care pharmacogenetic testing company, confirms that in order to
support the further drawdown and delivery of its £5M Equity
Prepayment facility that was announced on 31 March 2023,
application has been made for the Admission to trading on AIM of
4,690,665 new Ordinary Shares of 1.5p each ("New Ordinary
Shares"). This application for listing is to satisfy all
amounts currently outstanding under the Equity Prepayment
facility.
Admission of the New Ordinary Shares
("Admission") is expected to occur on 9 April 2024. Following
Admission, the New Ordinary Shares will rank pari passu in all
respects with the Company's existing ordinary
shares.
Following Admission the Company's
issued share capital will consist of 143,141,481 Ordinary Shares of
1.5p each and this figure may be used by shareholders as the
denominator for the calculations by which they should determine if
they are required to notify their interest in, or change to their
interest in, the Company under the FCA's Disclosure Guidance and
Transparency Rules.
For further details please
contact:
|
genedrive plc
|
+44 (0)161
989 0245
|
|
James Cheek: CEO / Russ Shaw:
CFO
|
|
|
|
|
|
Peel
Hunt LLP (Nominated Adviser and Broker)
|
+44 (0)20
7418 8900
|
|
James Steel / Patrick
Birkholm
|
|
|
|
|
|
Walbrook PR Ltd (Media & Investor
Relations)
|
+44 (0)20
7933 8780 or genedrive@walbrookpr.com
|
|
Anna Dunphy
|
+44
(0)7876 741 001
|
About genedrive plc (http://www.genedriveplc.com)
genedrive plc is a pharmacogenetic
testing company developing and commercialising a low cost, rapid,
versatile, simple to use and robust point of need pharmacogenetic
platform for the diagnosis of genetic variations. This helps
clinicians to quickly access key genetic information that will help
them make the right choices over the right medicine or dosage to
use for an effective treatment. Based in the UK, the Company is at
the forefront of work on Point of Care pharmacogenetics.
Pharmacogenetics looks at how your genetics impacts a medicines
ability to work for you. Therefore, by using pharmacogenetics,
medicines can be made safer and more effective. The Company has
launched its flagship product, the Genedrive® MT-RNR1 ID Kit, which
is a single-use disposable cartridge which circumvents the
requirement for cold chain logistics by providing temperature
stable reagent test kits for use on their proprietary test
platform. This test allows clinicians to make a decision on
antibiotic use within 26 minutes, ensuring vital care is delivered
with no negative impact on the patient pathway.
The Company has a clear commercial
strategy focused on accelerating growth through maximising
in-market sales, geographic and portfolio expansion and strategic
M&A, and operates out of its facilities in Manchester.